[go: up one dir, main page]

MX9707944A - Composiciones de oligosacaridos inmunigenicos e inmunoestimulatorios y metodos para fabricarlos y utilizarlos. - Google Patents

Composiciones de oligosacaridos inmunigenicos e inmunoestimulatorios y metodos para fabricarlos y utilizarlos.

Info

Publication number
MX9707944A
MX9707944A MX9707944A MX9707944A MX9707944A MX 9707944 A MX9707944 A MX 9707944A MX 9707944 A MX9707944 A MX 9707944A MX 9707944 A MX9707944 A MX 9707944A MX 9707944 A MX9707944 A MX 9707944A
Authority
MX
Mexico
Prior art keywords
methods
compositions
immunogenic
making
oligosaccharide
Prior art date
Application number
MX9707944A
Other languages
English (en)
Inventor
Andrew J Malcolm
Original Assignee
Alberta Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/482,626 external-priority patent/US5695768A/en
Priority claimed from US08/477,497 external-priority patent/US5866132A/en
Priority claimed from CA002153733A external-priority patent/CA2153733A1/en
Priority claimed from CA002153730A external-priority patent/CA2153730A1/en
Application filed by Alberta Res Council filed Critical Alberta Res Council
Publication of MX9707944A publication Critical patent/MX9707944A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invencion proporciona composiciones de oligosacáridos inmunogénicos y métodos para fabricarlos y utilizarlos. En particular, las composiciones comprenden oligosacáridos acoplados covalentemente a una proteína portadora, en donde el conjugado resultante ha mostrado contener epítopes inmunogénicos específicos provoca una respuesta protectivamente inmunogénica. Esta invencion también proporciona composiciones que comprenden un oligosacárido de S. Pneumoniae del serotipo 8 util para estimular una respuesta inmune a un antígeno, métodos para proporcionar inmunizacion protectora contra un patogeno bacteriano utilizando estas composiciones, métodos de aumentar una respuesta inmunogénica a un antígeno al administrar estas composiciones de oligosacáridos de S. Pneumoniae del serotipo 8 junto con el antígeno, y los métodos de fabricar composiciones imunoestimulatorias descritas anteriormente.
MX9707944A 1995-06-07 1997-10-15 Composiciones de oligosacaridos inmunigenicos e inmunoestimulatorios y metodos para fabricarlos y utilizarlos. MX9707944A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/482,626 US5695768A (en) 1995-06-07 1995-06-07 Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
US08/477,497 US5866132A (en) 1995-06-07 1995-06-07 Immunogenic oligosaccharide compositions
CA002153733A CA2153733A1 (en) 1995-07-12 1995-07-12 Immunogenic oligosaccharide compositions
CA002153730A CA2153730A1 (en) 1995-07-12 1995-07-12 Immunostimulating activity of streptococcus pneumoniae serotype 8 oligosaccharides

Publications (1)

Publication Number Publication Date
MX9707944A true MX9707944A (es) 1998-06-30

Family

ID=27427244

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9707944A MX9707944A (es) 1995-06-07 1997-10-15 Composiciones de oligosacaridos inmunigenicos e inmunoestimulatorios y metodos para fabricarlos y utilizarlos.

Country Status (10)

Country Link
EP (1) EP0831894A1 (es)
JP (1) JPH11506110A (es)
KR (1) KR19990007777A (es)
AU (1) AU725279B2 (es)
CZ (1) CZ327897A3 (es)
IL (1) IL121585A0 (es)
MX (1) MX9707944A (es)
NO (1) NO974727L (es)
NZ (1) NZ309713A (es)
WO (1) WO1996040225A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2264735C (en) * 1996-08-27 2008-01-29 Chiron Corporation Neisseria meningitidis serogroup b glycoconjugates and methods of using the same
US6451317B1 (en) * 1997-07-17 2002-09-17 Baxter International Inc. Immunogenic conjugates comprising a Group B meningococcal porin and an H influenzae polysaccharide
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
CA2329897A1 (en) * 1998-04-28 1999-11-04 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
US6436653B1 (en) 1998-12-15 2002-08-20 Exiqon A/S Method for introduction of reporter groups into bacterial lipopolysaccharide-derived carbohydrates and the subsequent coupling of such derivatives onto solid surfaces
CN101260149B (zh) * 2000-06-20 2016-05-11 魁北克益得生物医学公司 链球菌抗原
US9125951B2 (en) * 2009-06-22 2015-09-08 Wyeth Llc Compositions and methods for preparing Staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
EP2870974A1 (en) * 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
RU2771293C2 (ru) * 2014-01-21 2022-04-29 Пфайзер Инк. Иммуногенные композиции, содержащие конъюгированные капсульные сахаридные антигены, и их применение
EP3197907B1 (en) * 2014-09-26 2019-09-04 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Vaccines against streptococcus pneumoniae serotype 8
EP3000820A1 (en) * 2014-09-26 2016-03-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic vaccines against Streptococcus pneumoniae serotype 8
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
SG11201900789VA (en) 2016-08-05 2019-02-27 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
EP3493837B1 (en) 2016-08-05 2022-08-31 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
KR102738954B1 (ko) * 2017-09-07 2024-12-06 머크 샤프 앤드 돔 엘엘씨 담체 단백질에의 접합을 위한 폐렴구균 폴리사카라이드의 제제화 방법
WO2019152925A1 (en) 2018-02-05 2019-08-08 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
US11147864B2 (en) 2018-02-05 2021-10-19 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
EP3782642A4 (en) 2018-04-18 2022-04-13 SK Bioscience Co., Ltd. Streptococcus pneumoniae capsular polysaccharides and immunogenic conjugate thereof
WO2020121159A1 (en) * 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
CN113607939B (zh) * 2021-08-05 2024-10-22 艾美探索者生命科学研发有限公司 肺炎球菌多糖结合疫苗各型结合原液吸附率测定方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
ATE107703T1 (de) * 1986-04-16 1994-07-15 Brigham & Womens Hospital Bakterielle antigene, antikörper, impfstoffe und deren herstellung.
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2098839C (en) * 1990-12-18 2001-03-13 Suhail Ahmad Dialysate production system with dialysate pellets
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae

Also Published As

Publication number Publication date
NO974727L (no) 1997-12-08
IL121585A0 (en) 1998-02-08
NO974727D0 (no) 1997-10-13
AU5994496A (en) 1996-12-30
AU725279B2 (en) 2000-10-12
WO1996040225A1 (en) 1996-12-19
KR19990007777A (ko) 1999-01-25
NZ309713A (en) 1999-11-29
JPH11506110A (ja) 1999-06-02
CZ327897A3 (cs) 1998-02-18
EP0831894A1 (en) 1998-04-01

Similar Documents

Publication Publication Date Title
MX9707944A (es) Composiciones de oligosacaridos inmunigenicos e inmunoestimulatorios y metodos para fabricarlos y utilizarlos.
AU8483391A (en) Improved oligosaccharide conjugate vaccines
GR3035081T3 (en) Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
GB9713156D0 (en) Vaccines
WO2000056360A3 (en) Vaccine against antigens from bacteriae
ES8707861A1 (es) Un metodo para preparar un conjugado inmunogeno
WO1999055730A3 (en) Polyepitope carrier protein
AU3065489A (en) T-cell epitope as carriers molecule for conjugate vaccines
HK1041825A1 (en) A polysaccharide-protein conjugate or oligosaccharide-protein conjugate, a method for producing the same, and its uses thereof
EP0866133A3 (en) A group b streptococcus vaccine
WO2001037863A3 (en) Compositions comprising neisseria meningitidis antigens from serogroups b and c as well as a further antigen
HUT50048A (en) Process for producing streptococcus protein antigen and pharmaceutical compositions comprising same
CA2145397A1 (en) Group b streptococcus type ii and type v polysaccharide-protein conjugate vaccines
AU6832398A (en) Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
WO1999052548A3 (en) Conjugate vaccines for the prevention of dental caries
Midwinter et al. Vaccination of mice with lipopolysaccharide (LPS) and LPS-derived immuno-conjugates from Leptospira interrogans
CA2139217A1 (en) Vaccine composition for eliciting an immune response against n-glycolylated gangliosides and its use for cancer treatment
AU1991097A (en) Dialdehydes as immunostimulatory adjuvants and cross-linkers for producing immunogenic preparations and generating pressure and cross-linked treated cells for enhancing and augmenting the immune response against cancers, tumors and pathogenic diseases
NZ500151A (en) A general method for attaching DNA molecule comprising non-antibody target molecule (eg. CTLA-4 or L-selectin), antigen or epitope sequence, and optionally a polypeptide sequence
AU3991899A (en) Verotoxin b subunit for immunization
CA2133108A1 (en) Pasteurella haemolytica type a-1 bacterin-toxoid vaccine
Anderson Immunogenic conjugates.
AU2579600A (en) Product and method for obtaining specific immunisation with one or more antigens
ES2092960A1 (es) Gen de la proteina 1 de union a transferrina (tbp1) de actinobacillus pleuropneumoniae, utilizacion de esta en la preparacion de productos para la vacunacion contra la pleuroneumonia y en reactivos de diagnostico.
WO1990015132A3 (en) Cloned treponema hyodysenteriae endoflagellar antigen

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees